Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
befunolol
- Development stage
- Unknown
- Lead developer
- Kaken Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Befunolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) primarily used in the treatment of glaucoma. It lowers intraocular pressure by reducing aqueous humor production in the eye. Befunolol exhibits both beta-1 and beta-2 adrenergic blocking activity and is typically administered as an ophthalmic solution for topical use. The drug was developed to provide effective intraocular pressure reduction with minimal systemic side effects due to its local application.
- Brand names
- BenfuranBentosBefunolol Hydrochloride
- Other names
- befunolol hydrochloride
02
Targets
ADRB1 (β1)
Beyond the preview
Go deeper on befunolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on befunolol.